Back to Dermatology

OUR EXPERTISE AND SERVICES AVAILABLE IN

Atopic Dermatitis

Overview

Spherix’s coverage of the atopic dermatitis market focuses on the monumental shift in the treatment paradigm, particularly the expansion of biologics and JAK inhibitors.

Services Available

Trending market evolution

  • Atopic Dermatitis (US) - quarterly, n=100

  • Atopic Dermatitis (EU) - semiannual, n=250

Exploring the patient journey

  • Moderate to Severe Atopic Dermatitis (US) - n=1,000 patient charts

  • Moderate to Severe Atopic Dermatitis (EU) - n=1,250 patient charts

Benchmarking new brand performance

  • Abrocitinib (Pfizer) in Atopic Dermatitis (US)*

  • Olumiant (Lilly) in Atopic Dermatitis (US)*

  • Opzelura (Incyte) in Atopic Dermatitis (US)

  • Rinvoq (AbbVie) in Atopic Dermatitis (US)*

  • Tralokinumab (LEO) in Atopic Dermatitis (US)*

*Pending approvals and launch

Gauging impact of disruptive events

  • Multi-Specialty Impact of COVID-19 (US)

Learn more about our services

  • HOW CAN WE PARTNER TOGETHER?

    Get more information on Atopic Dermatitis Coverage